Supplementary Tables 1-4 from Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy

Supplementary Tables 1-4<p>Table S1 shows SNPs previously reported to be associated with oxaliplatin treatment. Table S2 presents detectable effect sizes at 85% power and type I error of 0.05 and 4.7 x 10-4 (corresponding to Bonferroni corrected p-value) for all endpoints based on minor allele frequency of genetic variants. Table S3-4 shows SNP associations with first-line oxaliplatin treatment for all endpoints in stage II-III CRC patients (Table S3) and mCRC patients (Table S4).</p>